A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 6, 2008, Pages 419-423

  Cooper, Curtis ^a   Hutton, Brian ^a   Fergusson, Dean ^a   Mills, Edward ^b   Klein, Marina B ^c   Boivin, Guy ^d   Halperin, Scott ^e  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

HIV; Immunocompromised; Influenza; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; FLUVIRAL; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOCOMPETENCE; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MORBIDITY; PATIENT ASSESSMENT; PNEUMOCOCCAL INFECTION; PREVALENCE; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; SEROCONVERSION; SEROLOGY; SINGLE DRUG DOSE;

EID: 58149252070     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/419710     Document Type: Review

References (28)

1. Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP. Estimates of HIV prevalence and incidence in Canada, 2005. Can Commun Dis Rep 2006;32:165-74.
2. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990;98:33-7.
3. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000;31:604-6.
4. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002;20(Suppl 5):B29-32.
5. Health Canada. Progress towards Canadian target coverage rates in influenza and pneumococcal immunications. 〈http://www.phac-aspc.gc.ca/ publicat/ccdr-rmtc/01vol27/dr2710eb.html〉 (Version current at December 8, 2006).
6. Advisory Committee on Immunization Practices; Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-42. (Erratum in 2006;55:800).
7. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: A systematic review and meta-analysis. HIV Med 2008;9:57-61.
8. Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med 2001;164:2120-6.
9. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005;191:1442-50.
10. Conley LJ, Bush TJ, Buchbinder SP, Penley KA, Judson FN, Holmberg SD. The association between cigarette smoking and selected HIV-related medical conditions. AIDS 1996;10:1121-6.
11. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:441-6.
12. Neuzil KM, Reed GW, Mitchel E Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999;281:901-7.
13. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001;32:1784-91.
14. Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007;45:234-40.
15. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med 1987;109:545-9.
16. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:206-11.
17. Huang KL, Ruben FL, Rinaldo CR Jr, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987;257:2047-50.
18. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37.
19. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: A consecutive 3-year study. Vaccine 2000;18:3040-9.
20. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:430-3.
21. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:167-73.
22. Ranieri R, Veronelli A, Santambrogio C, Pontiroli AE. Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. AIDS Res Hum Retroviruses 2005;21:407-9.
23. Nichol KL. Booster doses of influenza vaccine. JAMA 1996;276:1857.
24. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262:779-83.
25. Iorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and seronegative ex-intravenous drug users. Vaccine 1997;15:97-102.
26. Antibody responses and reactogenicity of graded doses of inactivated influenza A/New Jersey/76 whole-virus vaccine in humans. J Infect Dis 1977;136(Suppl):S475-83.
27. Roos-Van Eijndhoven DG, Cools HJ, Westendorp RG, Ten Cate-Hoek AJ, Knook DL, Remarque EJ. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J Med Virol 2001;63:293-8.
28. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51.